Navigation Links
Fate Therapeutics Created by Leading Stem Cell Scientists to Pursue New Approaches to Stem Cell Therapies
Date:11/29/2007

ll scientists, research leaders, and drug development luminaries to join its Scientific Advisory Board:

-- Robert Langer, Sc.D.: Institute Professor of Chemical and Biomedical

Engineering, Massachusetts Institute of Technology

-- Ram Sasisekharan, Ph.D.: Professor of Biological Engineering & Health

Sciences and Technology, Massachusetts Institute of Technology

-- Ben Shapiro, M.D.: Retired Executive Vice President of Worldwide Basic

Research, Merck Research Laboratories

"Fate's timing is excellent," said Fate's Executive Vice President Tom St. John. "The science is now mature enough. Clear therapeutic modalities have emerged, and the cloud of political and ethical debate surrounding embryonic stem cells is now a thing of the past. We've got a real opportunity to prove that Fate's adult stem cell therapies are the future of medicine."

Before joining Fate, St. John was the Vice President of Therapeutic Development at ICOS Corporation overseeing all of ICOS' development programs.

World-class investment team lined up behind scientists

The unparalleled scientific team is backed by leading venture capital firms ARCH Venture Partners, Polaris Venture Partners, Venrock and OVP, all with successful track records in building some of the world's leading life sciences companies.

The syndicate group has a combined $7 billion under management. Ground-breaking biotechnology companies founded by the firms and their partners include Immunex, IDEC Pharmaceuticals, Gilead Sciences, Genetics Institute, Illumina, Centocor, Sepracor, Alnylam Pharmaceuticals, Athena Neurosciences, Aviron, Corixa, deCode Genetics, Geron, Glycofi, Ikaria, Millennium Pharmaceuticals, Momenta Pharmaceuticals, Sirna Therapeutics, Trubion Pharmaceuticals, Vical and XenoPort.

Fate Therapeutics was co-founded by Alex Rives, of ARCH Venture Partners. The company's board of directors includes Amir Nashat, General Partner,
'/>"/>

SOURCE Fate Therapeutics
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... 2, 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), ... regenerative medicine, today announced that it will release fourth ... on Tuesday, March 10, 2015 after the close of ... conference call and webcast on Tuesday, March 10, 2015 ... discuss the results and recent corporate developments. ...
(Date:3/2/2015)... 2015 Global Stem Cells ... with Shenzhen HANK Bioengineering Co., Ltd. and its ... will establish a stem cells training course in ... September 2015. , Shenzhen HANK is a biotechnology ... scientist, microbiologist and virologist, to integrate research, development, ...
(Date:2/28/2015)... Increasing its efforts to resolve the GMO ... episodes of The GMO TRUTH podcast on both ITunes and ... continues its mission to discover the truth and change the ... “uncover the truth about the GMOs in our food supply,” ... Podcast is an expansion of the documentary/investigative film-making methodology in ...
(Date:2/27/2015)... 2015  Pharmacyclics, Inc. (NASDAQ: PCYC ... its newly developed Bruton,s tyrosine kinase (BTK) inhibitor ... The results of these preclinical evaluations have been ... The feedback received from the Agency is supportive ... Additional preclinical work is required to begin a ...
Breaking Biology Technology:Asterias Biotherapeutics to Report Fourth Quarter and Full Year 2014 Results on March 10, 2015 2Global Stem Cells Group Announces Alliance with HANK Bioengineering Co., Ltd. in Shenzhen, China 2Global Stem Cells Group Announces Alliance with HANK Bioengineering Co., Ltd. in Shenzhen, China 3The Walk a Mile Project Launches “GMO Truth” Podcast 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3
... , , LOS ANGELES, Aug. 6 ... an 82 year-old Chinese female immigrant who suffered Stevens-Johnson Syndrome/Toxic Epidermal ... Defendant, an osteopathic physician and registered pharmacist, prescribed it to her ... did not have gout. The doctor claimed that she told ...
... , , OMAHA, Neb., Aug. 6 Transgenomic Inc. (OTC ... What: Transgenomic Inc. Second Quarter 2009 Earnings Release, ... Wednesday, August 12, 2009 @ 5:00 p.m. Eastern, Where: ... the Internet -- Simply log on to the web at the, ...
... , , , , ... drugs to combat Alzheimer,s began journey 8 years ago , , ... of a million" , , NEW YORK, Aug. 6 ... (ADDF) , have achieved a significant milestone in their development as they advance ...
Cached Biology Technology:The Law Offices of Brian D. Witzer Wins 6+ Million Dollar Verdict 2Webcast Alert: Transgenomic Inc. Announces Second Quarter 2009 Earnings Release Conference Call Webcast 2PharmatrophiX, Initially Funded by the Alzheimer's Drug Discovery Foundation, Announces Exclusive Global Collaboration with Elan 2PharmatrophiX, Initially Funded by the Alzheimer's Drug Discovery Foundation, Announces Exclusive Global Collaboration with Elan 3
(Date:2/23/2015)... , Feb. 23, 2015 NXT-ID, Inc. ... the "Company"), a biometric authentication company focused on the ... filed provisional patent 62114357 for DISTRIBUTED VOICE ... patent, NXT-ID introduces a new groundbreaking payment method. Payment ... payment account may only be accessed if both the ...
(Date:2/12/2015)... NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market, announced ... DISTRIBUTED METHOD AND SYSTEM TO IMPROVE COLLABORATIVE ... establishes NXT-ID,s position in the emerging "Internet of Things" ... for multiple devices to collaborate with one another to ...
(Date:2/5/2015)... , Feb. 5, 2015  Marken is starting ... company and has launched a new marketing campaign to ... Organization (CLO).  The new campaign focuses on First ... protocol and shipments. The first headline in ... aligns Marken,s priorities with its client,s priorities. Marken recognizes ...
Breaking Biology News(10 mins):NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Marken Launches New Patient-Centric Campaign 2
... surrounds the DNA of our cells could help develop treatments ... have discovered that the proteins within this coating known ... different organs of the body. This variation ... proteins in the protective seal to cause illness in some ...
... Daejeon, Republic of Korea, February 26, 2013The Korea Advanced ... a global energy and petrochemicals enterprise, signed on February ... Agreement) on joint collaborations in research and development of ... Agreement was subsequently concluded upon the signing of the ...
... is faced with some of the world,s worst pollution. Until ... a major contributor to that pollution human-caused nitrogen emissions ... biology professor and Stanford Woods Institute senior fellow Peter Vitousek ... deposited on land and water in China by way of ...
Cached Biology News:Cell discovery could hold key to causes of inherited diseases 2Launched the Saudi Aramco-KAIST CO2 Management Center in Korea 2Stanford scientists help shed light on key component of China's pollution problem 2
For relative and/or absolute quantification with standard accuracy requirements using MS or NMR instruments...
PxE thermal Cycler. 0.5ml block holds 48 0.5 ml tubes or 96 0.3 ml tubes. Adjustable height heated lid. Outstanding uniformity. Advanced control algorithms for reduced reaction times. User frien...
For testing the AQUA technique on your MS instruments....
0.2ml Gradient Block MBSR. Robot compatible block ejection mechanism. Stackable. (96 well block - holds 1 plate 0.2ml x 96 well plate)...
Biology Products: